These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 22111227)

  • 1. [Osteoporosis in castration therapy--a neglected field].
    Bratt O; Akesson K
    Lakartidningen; 2011 Sep 28-Oct 4; 108(39):1902-5. PubMed ID: 22111227
    [No Abstract]   [Full Text] [Related]  

  • 2. French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation.
    Briot K; Paccou J; Beuzeboc P; Bonneterre J; Bouvard B; Confavreux CB; Cormier C; Cortet B; Hannoun-Lévi JM; Hennequin C; Javier RM; Lespessailles E; Mayeur D; Mongiat Artus P; Vieillard MH; Debiais F
    Joint Bone Spine; 2019 Jan; 86(1):21-28. PubMed ID: 30287350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Prevention and treatment of osteoporosis during treatment of non-metastatic prostate cancer].
    Eiken PA; Langdahl BL; Eiken FL; Walter S; Poulsen MH; Abrahamsen B
    Ugeskr Laeger; 2011 Nov; 173(48):3093-6. PubMed ID: 22118650
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Osteoporosis in men treated with androgen deprivation therapy for prostate cancer.
    Ross RW; Small EJ
    J Urol; 2002 May; 167(5):1952-6. PubMed ID: 11956415
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk of fracture after androgen deprivation for prostate cancer.
    Walsh PC
    J Urol; 2005 Sep; 174(3):929-30. PubMed ID: 16093991
    [No Abstract]   [Full Text] [Related]  

  • 6. Diagnosis and management of treatment-related osteoporosis in men with prostate carcinoma.
    Smith MR
    Cancer; 2003 Feb; 97(3 Suppl):789-95. PubMed ID: 12548577
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Osteoporosis during androgen deprivation therapy for prostate cancer.
    Smith MR
    Urology; 2002 Sep; 60(3 Suppl 1):79-85; discussion 86. PubMed ID: 12231056
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer.
    Smith MR; Eastham J; Gleason DM; Shasha D; Tchekmedyian S; Zinner N
    J Urol; 2003 Jun; 169(6):2008-12. PubMed ID: 12771706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Endocrine treatment of prostate cancer.
    Tammela T
    J Steroid Biochem Mol Biol; 2004 Nov; 92(4):287-95. PubMed ID: 15663992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risedronate prevents early bone loss and increased bone turnover in the first 6 months of luteinizing hormone-releasing hormone-agonist therapy for prostate cancer.
    Taxel P; Dowsett R; Richter L; Fall P; Klepinger A; Albertsen P
    BJU Int; 2010 Nov; 106(10):1473-6. PubMed ID: 20456336
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative study of the protective effect of different intravenous bisphosphonates on the decrease in bone mineral density in patients submitted to radical prostatectomy undergoing androgen deprivation therapy. A prospective open-label controlled study.
    Rodrigues P; Hering FO; Bruna P; Meller A; Afonso Y
    Int J Urol; 2007 Apr; 14(4):317-20. PubMed ID: 17470161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Health care cost associated with prostate cancer, androgen deprivation therapy and bone complications.
    Krupski TL; Foley KA; Baser O; Long S; Macarios D; Litwin MS
    J Urol; 2007 Oct; 178(4 Pt 1):1423-8. PubMed ID: 17706711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone metastases and bone loss medical treatment in prostate cancer patients.
    Safriadi F
    Acta Med Indones; 2013 Jan; 45(1):76-80. PubMed ID: 23585414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progressive osteoporosis during androgen deprivation therapy for prostate cancer.
    Daniell HW; Dunn SR; Ferguson DW; Lomas G; Niazi Z; Stratte PT
    J Urol; 2000 Jan; 163(1):181-6. PubMed ID: 10604342
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Re: Diethylstilbesterol revisited: androgen deprivation, osteoporosis an prostate cancer.
    Pitts WR
    J Urol; 2002 Jul; 168(1):201; author reply 201. PubMed ID: 12050534
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevent and manage bone loss in men receiving androgen deprivation therapy.
    Becze E
    ONS Connect; 2010 Apr; 25(4):18-9. PubMed ID: 20437748
    [No Abstract]   [Full Text] [Related]  

  • 18. Osteoporosis after orchiectomy for prostate cancer.
    Daniell HW
    J Urol; 1997 Feb; 157(2):439-44. PubMed ID: 8996327
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Are we doing enough to promote bone health in men with prostate cancer?
    Boyd LA
    Urol Nurs; 2008 Dec; 28(6):412-3. PubMed ID: 19241777
    [No Abstract]   [Full Text] [Related]  

  • 20. Fracture risk in Danish men with prostate cancer: a nationwide register study.
    Abrahamsen B; Nielsen MF; Eskildsen P; Andersen JT; Walter S; Brixen K
    BJU Int; 2007 Oct; 100(4):749-54. PubMed ID: 17822455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.